Lupin is served with two observations from US FDA for Pithampur unit


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Lupin
FDA observations for Lupin though it passed the other regulatory benchmarks

Pharma major Lupin Limited (Lupin) who announced, the successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom (UK) at its three manufacturing units in Pithampur (India) got two observations from FDA.

According to Lupin,US health regulator has issued two observations after inspection of the company’s Madhya Pradesh facility. The inspection of the company’s Pithampur Unit-I facility by the United States Food and Drug Administration (US FDA) has been completed, Lupin said in a filing to BSE.

The inspection carried out between February 3 and February 11, 2020, closed with two 483 observations, it added. An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts. It notifies the company’s management of objectionable conditions at the facility.

“We uphold the highest standards of quality and compliance across our manufacturing operations and are committed to consistently produce and distribute products of the highest quality,” Nilesh Gupta, MD, Lupin said

The inspection for the three units at Pithampur closed with no critical observation and one major observation.

Tags : #Lupin #Usfda #2observations #Pithampurunit

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026